Le Lézard
Classified in: Health
Subjects: CCA, BFA, PET, FVT

Aratana Therapeutics to Report Third Quarter 2017 Financial Results


LEAWOOD, Kan., Oct. 5, 2017 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, will host a live conference call on Friday, November 3, 2017 at 8:30 a.m. ET to discuss financial results from the third quarter ended September 30, 2017.

Aratana Therapeutics logo

Interested participants and investors may access the audio webcast or use the conference call dial-in:

     1 (866) 364-3820 (U.S.) 
     1 (855) 669-9657 (Canada)
     1 (412) 902-4210 (International)

A replay of the third quarter results teleconference will be available the same day of the event by approximately 11 a.m. ET and an audio webcast will be accessible for 90 days in the Aratana Investor Room. For a replay of the call, use the below dial-in and conference ID 10112622:

     1 (877) 344-7529 (U.S.) 
     1 (855) 669-9658 (Canada
     1 (412) 317-0088 (International)

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to dogs and cats in a capital and time efficient manner. The company's pipeline includes therapeutic candidates for the potential treatment of pain, inappetence, viral diseases, allergy, cancer and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com.

Contacts
For investor inquires:
Craig Tooman
[email protected] 
(913) 353-1026

For media inquiries:
Rachel Reiff
[email protected] 
(913) 353-1050

SOURCE Aratana Therapeutics, Inc.


These press releases may also interest you

at 12:05
VirtualHealth is excited to share that its HELIOS platform was named the winner of a Bronze Stevie® Award in the Healthcare Technology Solution category in The 22nd Annual American Business Awards® today. More than 3,700 nominations were submitted...

at 12:02
On May 1, 2024, Toronto Public Health (TPH) will host Diverse Dialogues: Stigma & Breaking Barriers. The event will bring together distinguished speakers to explore the challenging and thought-provoking topic about how negative labels and biases...

at 11:56
As the demand for cosmetic procedures continues to rise, patients are seeking more advanced and effective options for achieving a youthful and rejuvenated appearance. In response to this, Dr. Ronald Demeo has introduced the Next Level Deep Plane Face...

at 11:50
Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company") today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited)...

at 11:34
At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided: Resolution in accordance with the Board's proposed dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the...

at 11:25
TimelyCare, higher education's most trusted virtual health and well-being provider, has earned recognition as one of the World's Best Digital Health Companies by Newsweek, and has been awarded five Top Workplaces Awards for culture excellence....



News published on and distributed by: